Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William Wierda

Showing results (141-150 of 181) with videos related to

Pageof 19
Sort By:
Leukemia|September 25, 2024
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphomaFarhad Ravandi, Jayastu Senapati, Nitin Jain, et al.
Blood|August 25, 2017
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatmentGhayas C Issa, Hagop M Kantarjian, Graciela Nogueras Gonzalez, et al.
Leukemia Research|April 17, 2022
Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemiaFatima Zahra Jelloul, Richard Yang, Sofia Garces, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End ResultsKoji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Acta Haematologica|May 12, 2020
Treating Leukemia in the Time of COVID-19Shilpa Paul, Caitlin R Rausch, Nitin Jain, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Pageof 19

Showing results (141-150 of 181) with videos related to

Sort By:
Pageof 19
Leukemia|September 25, 2024
Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphomaFarhad Ravandi, Jayastu Senapati, Nitin Jain, et al.
Blood|August 25, 2017
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatmentGhayas C Issa, Hagop M Kantarjian, Graciela Nogueras Gonzalez, et al.
Leukemia Research|April 17, 2022
Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemiaFatima Zahra Jelloul, Richard Yang, Sofia Garces, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 10, 2023
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End ResultsKoji Sasaki, Kiyomi Morita, Hagop Kantarjian, et al.
Acta Haematologica|May 12, 2020
Treating Leukemia in the Time of COVID-19Shilpa Paul, Caitlin R Rausch, Nitin Jain, et al.
American Journal of Hematology|January 5, 2023
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up resultsHagop Kantarjian, Nicholas J Short, Nitin Jain, et al.
Oncoimmunology|April 11, 2018
Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapySimon Schliffke, Mariela Sivina, Ekaterina Kim, et al.
The Lancet. Haematology|December 4, 2018
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 studyElias Jabbour, Nicholas J Short, Farhad Ravandi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
The Lancet. Haematology|January 17, 2017
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trialPreetesh Jain, Michael Keating, Sarah Renner, et al.
Pageof 19